It has been reported that immunoreactive trypsinogen concentrations were raised in blood in infants with cystic fibrosis.' A number of subsequent trials have shown that immunoreactive trypsinogen could be estimated on dried blood spots as a screening assay for cystic fibrosis in the new born period. These reports showed encouraging results, and thus it was decided that it would be useful to assess the ability of this assay to detect cystic fibrosis in conjunction with the existing screening programme for phenylketonuria and congenital hypothyroidism in Northern Ireland.
Methods
Blood specimens, obtained by heel prick and collected on to filter paper cards, were taken between 5 and 8 days of age from all infants born in Northern Ireland. Before August 1983 these samples were used to screen for phenylketonuria and congenital hypothyroidism. Since August 1983 measurement of immunoreactive trypsinogen has been included as a screening test for cystic fibrosis. A second heel prick sample was obtained from all infants whose initial trypsinogen value was high, usually at 3-4 weeks of age. If the repeat trypsinogen concentration was also high the baby was seen by a paediatrician with experience in management of cystic fibrosis, and a full clinical examination and sweat test carried out; the child was usually 4-6 weeks old at this time.
Measurement of immunoreactive trypsinogen, on blood spot specimens, was carried out using the CIS Neonatal Trypsin Radioimmunoassay (CIS (UK) Ltd). The within assay coefficients of variation for the three concentrations of immunoreactive trypsinogen, 24, 55, and 108 [tg/l, were 8-5%, 6-1%, and 5-2%, respectively. The between assay coefficients of variation at the same concentrations were 9.3%, 8 3%, and 7-7%, respectively. From a precision profile for the assay the range for which the between assay coefficient of variation is <10% has been shown to be 10-140 sg/l. To establish a reference range for the assay immunoreactive trypsinogen measurements were carried out on 4000 infants born during June and July 1983. These results were not included in the four year period of assessment of the assay, and one infant born during June Table 2 shows that of those children with cystic fibrosis and low immunoreactive trypsinogen values on screening, only three in the four year period were asymptomatic; these children were investigated after the diagnosis of cystic fibrosis in siblings. The remainder had pronounced symptoms, the most important feature being failure to thrive, attributed in four cases to repeated pulmonary infections and to persistent diarrhoea in the remainder.
EFFECT OF SCREENING ON THE AGE AT DIAGNOSIS Table 3 shows that the median age at which the The region of Northern Ireland is a small one, with an annual birth rate of about 28 000, and there is not a great deal of population movement in and out of the region. There is one single large referral unit in Belfast for patients with cystic fibrosis. On account of these factors very few patients are lost to follow up, and this may contribute to the fact that in this paper we describe a higher incidence of false negative results than have been indicated in previous reports. Three infants who were false negatives, but with results close to our cut off value in the first year of screening, would have been detected if the lower cut off value had applied throughout the time of screening. Two further false negative results were caused by one high followed by a low trypsinogen concentration, and this may have been because of incorrect timing of the second specimens, as initially raised trypsinogen concentrations in cystic fibrosis are known to fall to within the normal range at varying rates in different infants.3 In the remaining nine false negatives the results of screening were well within the normal limits, and no explanation could be put forward to suggest why the results were low in infants with cystic fibrosis. Of 12 infants born with meconium ileus, 10 had low results on screening, a findinf6which has been reported in a number of studies. As children born with meconium ileus should be investigated for cystic fibrosis their low results on screening should not cause a serious diagnostic problem, although it is important to emphasise the relationship between meconium ileus and low concentrations of immunoreactive trypsinogen. From the results in table 3 it can be seen that the median age at diagnosis for the screened population is less than that for children born in the three years before screening. It is possible that additional false negative cases will be identified in the future. It should be noted, however, that in the last seven years the number of children in Northern Ireland shown to have cystic fibrosis has remained reasonably constant, with 13-16 children being diagnosed each year. In addition the overall known incidence of cystic fibrosis in Northern Ireland during the last four years is 1/1807, which is a high incidence, making it unlikely that there are many more unidentified infants with cystic fibrosis born during this period of time.
In conclusion, this screening programme has resulted in a lowering in the median age at which the diagnosis of cystic fibrosis is made and a considerable reduction in the anxiety of parents with an undiagnosed sick child. It is also possible to offer genetic counselling to these parents. It must be recognised that in our hands immunoreactive trypsinogen has not proved to be an ideal screening test for cystic fibrosis. The clinicians involved in the study, however, feel that because of the earlier age at diagnosis in a large number of infants with cystic fibrosis the screen should continue for a further period of time. It seems likely that other tests that closely reflect the underlying genetic or metabolic abnormalities will soon become available.
